P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.

• David H. Vesole,
• Jesus Berdeja,
• Jeffrey Matous,
• Suzanne Trudel,
• Henning Schade,
• Pamela Munster,
• Savannah Berkeley,
• Benjamin Sun,
• Tom Martin

Affiliations

David H. Vesole

1 John Theurer Cancer center, Myeloma Division, Hackensack, United States

Jesus Berdeja

2 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, United States

Jeffrey Matous

3 Colorado Blood Cancer Institute and Sarah Canon Research Inst., Denver, United States

Suzanne Trudel

4 University Health Network, Princess Margaret Hospital, Toronto, Canada

Henning Schade

3 Colorado Blood Cancer Institute and Sarah Canon Research Inst., Denver, United States

Pamela Munster

5 University of California San Francisco Parnassus Campus, Hematology/Oncology, San Francisco, United States

Savannah Berkeley

5 University of California San Francisco Parnassus Campus, Hematology/Oncology, San Francisco, United States

Benjamin Sun

5 University of California San Francisco Parnassus Campus, Hematology/Oncology, San Francisco, United States

Tom Martin

5 University of California San Francisco Parnassus Campus, Hematology/Oncology, San Francisco, United States